NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/11/2023
Back to search
Official data from USPTO
EMPOWERING OLIGONUCLEOTIDE THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
EMPOWERING OLIGONUCLEOTIDE THERAPEUTICS
ST13
US500000097622958Class
42
Filing
97622958
Registration
7025936
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
15
Latest update
08/24/2023
Trademark type
Word
Nice classes
42
Filing date
10/07/2022
Registration date
04/11/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/11/2023
Last transaction
08/24/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
2021-04-00
First use in commerce
2021-04-00
Drawing code
4
Owner type
03
Owner location
Cambridge, MA, US
Examiner
FOSDICK, GEOFFREY A
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
PepGen Inc.
Representatives
Jessica L. Rothstein GOODWIN PROCTER LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development of therapeutics for the treatment of neuromuscularneurologic and other diseases; Research and development of peptide-conjugated therapeutics for the treatment of neuromuscularneurologic and other diseases; Research and development of a drug delivery platform and conjugate therapeutics for the treatment of neuromuscularneurologic and other diseases
Publications
History of USPTO decisions and trademark events.
15 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/11/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/24/2023
PUBO
PUBLISHED FOR OPPOSITION
01/24/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/04/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/19/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/16/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/15/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/15/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/02/2022
GNRT
NON-FINAL ACTION E-MAILED
12/02/2022
CNRT
NON-FINAL ACTION WRITTEN
12/02/2022
DOCK
ASSIGNED TO EXAMINER
12/01/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/24/2022
NWAP
NEW APPLICATION ENTERED
10/11/2022
Continuous trademark protection
Get notified about every new filing that threatens EMPOWERING OLIGONUCLEOTIDE THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.